Journal of Zhejiang University SCIENCE B

, Volume 9, Issue 2, pp 85–89 | Cite as

BRCA1/2 associated hereditary breast cancer



Breast cancer is one of the leading causes of death in women today. Some of the patients are hereditary, with a large proportion characterized by mutation in BRCA1 and/or BRCA2 genes. In this review, we provide an overview of these two genes, focusing on their relationship with hereditary breast cancers. BRCA1/2 associated hereditary breast cancers have unique features that differ from the general breast cancers, including alterations in cellular molecules, pathological bases, biological behavior, and a different prevention strategy. But the outcome of BRCA1/2 associated hereditary breast cancers still remains controversial; further studies are needed to elucidate the nature of BRCA1/2 associated hereditary breast cancers.

Key words

BRCA1 BRCA2 Hereditary breast cancer 

Document code

CLC number



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., Zlotogora, J., Heching, N., Peretz, T., 1997. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-on-set breast cancer patients among Ashkenazi women. Am. J. Hum. Genet., 60(3):505–514.PubMedGoogle Scholar
  2. American Cancer Society, 2007. Cancer Facts and Figures. p.3–9. 1x_Cancer_Facts__Figures_2007.asp
  3. Breast Cancer Linkage Consortium, 1997. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet, 349(9064):1505–1510.CrossRefGoogle Scholar
  4. Brekelmans, C.T.M., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H.T., Tilanus-Linthorst, M.M.A., Bartels, C.C.M., Kriege, M., van Geel, A.N., Crepin, C.M.G., Blom, J.C., et al., 2006. Survival and prognostic factors in BRCA1-associated breast cancer. Ann. Oncol., 17(3): 391–400. [doi:10.1093/annonc/mdj095]PubMedCrossRefGoogle Scholar
  5. Chen, J.J., Silver, D., Cantor, S., Livingston, D.M., Scully, R., 1999. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res., 59(7 Suppl.):1752–1756.Google Scholar
  6. Claus, E.B., Schildkraut, J.M., Thompson, W.D., Risch, N.J., 1996. The genetic attributable risk of breast and ovarian cancer. Cancer, 77(11):2318–2324. [doi:10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z]PubMedCrossRefGoogle Scholar
  7. Cortez, D., Wang, Y., Qin, J., Elledge, S.J., 1999. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science, 286(5442):1162–1166. [doi:10.1126/science.286.5442.1162]PubMedCrossRefGoogle Scholar
  8. Easton, D.F., Bishop, D.T., Ford, D., Crockford, G.P., 1993. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet., 52(4):678–701.PubMedGoogle Scholar
  9. Einbeigi, Z., Bergman, A., Kindblom, L.G., Martinsson, T., Meis-Kindblom, J.M., Nordling, M., Suurküla, M., Wahlström, J., Wallgren, A., Karlsson, P., 2001. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur. J. Cancer, 37(15):1904–1909. [doi:10.1016/S0959-8049(01)00223-4]PubMedCrossRefGoogle Scholar
  10. El-Tamer, M., Russo, D., Troxel, A., Bernardino, L.P., Mazziotta, R., Estabrook, A., Ditkoff, B., Schnabel, F., Mansukhani, M., 2004. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann. Surg. Oncol., 11(2):157–164. [doi:10.1245/ASO.2004.05.018]PubMedCrossRefGoogle Scholar
  11. Foulkes, W.D., Stefansson, I.M., Chappuis, P.O., Begin, L.R., Goffin, J.R., Wong, N., Trudel, M., Akslen, L.A., 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst., 95(19): 1482–1485. [doi:10.1093/jnci/djg050]PubMedGoogle Scholar
  12. Geiger, A.M., Nekhlyudov, L., Herrinton, L.J., Rolnick, S.J., Greene, S.M., West, C.N., Harris, E.L., Elmore, J.G., Altschuler, A., Liu, I.L., et al., 2007. Quality of life after bilateral prophylactic mastectomy. Ann. Surg. Oncol., 14(2):686–694. [doi:10.1245/s10434-006-9206-6]PubMedCrossRefGoogle Scholar
  13. Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B., King, M.C., 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250(4988):1684–1689. [doi:10.1126/science.2270482]PubMedCrossRefGoogle Scholar
  14. Hashizume, R., Fukuda, I., Maeda, H., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H., Ohta, T., 2001. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem., 276(18):14537–14540. [doi:10.1074/jbc.C000881200]PubMedCrossRefGoogle Scholar
  15. Honrado, E., Benítez, J., Palacios, J., 2005. The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod. Pathol., 18(10):1305–1320. [doi:10.1038/modpathol.3800453]PubMedCrossRefGoogle Scholar
  16. King, M.C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., Tait, J., Ford, L., Dunn, B.K., Costantino, J., et al., 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA, 286(18):2251–2256. [doi:10.1001/jama.286.18.2251]PubMedCrossRefGoogle Scholar
  17. Lakhani, S.R., Jacquemier, J., Sloane, J.P., Gusterson, B.A., Anderson, T.J., Vijver, M.J., Farid, L.M., Venter, D., Antoniou, A., Storfer-Isser, A., et al., 1998. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst., 90(15):1138–1145. [doi:10.1093/jnci/90.15.1138]PubMedCrossRefGoogle Scholar
  18. Lakhani, S.R., van de Vijver, M.J., Jacquemier, J., Anderson, T.J., Osin, P.P., McGuffog, L., Easton, D.F., 2002. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol., 20(9):2310–2318. [doi:10.1200/JCO.2002.09.023]PubMedCrossRefGoogle Scholar
  19. Lou, Z., Chini, C.C., Minter-Dykhouse, K., Chen, J., 2003. Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J. Biol. Chem., 278(16):13599–13602. [doi:10.1074/jbc.C300060200]PubMedCrossRefGoogle Scholar
  20. Meijers-Heijboer, H., van Geel, B., van Putten, W.L.J., Henzen-Logmans, S.C., Seynaeve, C., Menke-Pluymers, M.B., Bartels, C.C., Verhoog, L.C., van den Ouweland, A.M.W., Niermeijer, M.F., et al., 2001. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med., 345(3):159–164. [doi:10.1056/NEJM200107193450301]PubMedCrossRefGoogle Scholar
  21. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182):66–71. [doi:10.1126/science.7545954]PubMedCrossRefGoogle Scholar
  22. Moller, P., Evans, D.G., Reis, M.M., Gregory, H., Anderson, E., Maehle, L., Lalloo, F., Howell, A., Apold, J., Clark, N., et al., 2007. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int. J. Cancer, 121(5):1017–1020. [doi:10.1002/ijc.22789]PubMedCrossRefGoogle Scholar
  23. Narod, S.A., 2002. Modifiers of risk of hereditary breast and ovarian cancer. Nat. Rev. Cancer, 2(2):113–123. [doi:10.1038/nrc726]PubMedCrossRefGoogle Scholar
  24. Narod, S.A., Brunet, J.S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S.L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., Rios, P., et al., 2000. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet, 356(9245): 1876–1881. [doi:10.1016/S0140-6736(00)03258-X]PubMedCrossRefGoogle Scholar
  25. Perou, C.M., Sorlie, T., Eisen, M.B., Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et al., 2000. Molecular portraits of human breast tumours. Nature, 406(6797):747–752. [doi:10.1038/35021093]PubMedCrossRefGoogle Scholar
  26. Rennert, G., Bisland-Naggan, S., Barnett-Griness, O., Bar-Joseph, N., Zhang, S., Rennert, H.S., Narod, S.A., 2007. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med., 357:115–123. [doi:10.1056/NEJMoa070608]PubMedCrossRefGoogle Scholar
  27. Robson, M.E., Chappuis, P.O., Satagopan, J., Wong, N., Boyd, J., Goffin, J.R., Hudis, C., Roberge, D., Norton, L., Bégin, L.R., et al., 2004. A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res., 6(1):R8–R17. [doi:10.1186/bcr658]PubMedCrossRefGoogle Scholar
  28. Struewing, J.P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M.M., Collins, F.S., Brody, L.C., 1995. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat. Genet., 11(2):198–200. [doi:10.1038/ng1095-198]PubMedCrossRefGoogle Scholar
  29. Struewing, J.P., Tarone, R.E., Brody, L.C., Li, F.P., Boice, J.D., 1996. BRCA1 mutations in young women with breast cancer. Lancet, 347(9013):1493. [doi:10.1016/S0140-6736(96)91732-8]PubMedCrossRefGoogle Scholar
  30. Syrjakoski, K., Vahteristo, P., Eerola, H., Tamminen, A., Kivinummi, K., Sarantaus, L., Holli, K., Blomqvist, C., Kallioniemi, O.P., Kainu, T., Nevanlinna, H., 2000. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J. Natl. Cancer Inst., 92(18):1529–1531. [doi:10.1093/jnci/92.18.1529]PubMedCrossRefGoogle Scholar
  31. Tavtigian, S.V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., et al., 1996. The complete BRCA2 gene and mutations in chromosome 13q linked kindreds. Nat. Genet., 12(3):333–337. [doi:10.1038/ng0396-333]PubMedCrossRefGoogle Scholar
  32. Tirkkonen, M., Johannsson, O., Agnarsson, B.A., Olsson, H., Ingvarsson, S., Karhu, R., Tanner, M., Isola, J., Barkardottir, R.B., Borg, A., et al., 1997. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res., 57(7):1222–1227.PubMedGoogle Scholar
  33. Uyei, A., Peterson, S.K., Erlichman, J., Broglio, K., Yekell, S., Schmeler, K., Lu, K., Meric-Bernstam, F., Amos, C., Strong, L., et al., 2006. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: A single-institution study. Cancer, 107(12):2745–2751. [doi:10.1002/cncr.22352]PubMedCrossRefGoogle Scholar
  34. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., 1995. Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559):789–792. [doi:10.1038/378789a0]PubMedCrossRefGoogle Scholar
  35. Yu, V., Koehler, M., Steinlein, C., Schmid, M., Hanakahi, L. A., van Gool, A.J., West, S.C., Venkitaraman, A.R., 2000. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes. Dev., 14(11):1400–1406.PubMedGoogle Scholar
  36. Zelada-Hedman, M., Arver, B.W., Claro, A., Chen, J., Werelius, B., Kok, H., Sandelin, K., Håkansson, S., Andersen, T.I., Borg, A., et al., 1997. A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region. Cancer Res., 57(12):2474–2477.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Cancer Center, the First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations